MILAN, Italy and NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) -- Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announces that Richard Slansky is appointed as Chief Financial Officer (“CFO”) and proposes Anthony Marucci as independent member of the Board of Directors. The news follows the announcement of Stephen Squinto, PhD, as Chairman last November. Both Board appointments will be effective following their approval at the Genenta Shareholders’ Meeting on May 20, 2021.

See the rest here:
Genenta to Appoint Richard Slansky as CFO and Anthony Marucci as Board Member